https://www.selleckchem.com/pr....oducts/anacetrapib-m
Hemoglobin (Hb)-F inducers are known to improve Hb level and transfusion dependence in thalassemia. This pilot study was conducted to assess the efficacy and safety of Hb-F inducer thalidomide compared to hydroxyurea (HU) in Hb E-β thalassemia patients. This was a prospective interventional single-centre study with 45 Hb E-beta thalassemia patients equally divided into group-I (thalidomide+folic acid), group-II (HU+folic acid) and group-III (folic acid). Response was assessed at various time intervals with 12-months follow u
Like
Comment
Share
